38 citations
,
January 2009 in “Journal of Cutaneous Medicine and Surgery” A woman developed hair loss after starting a treatment with adalimumab, suggesting this medication might cause hair loss.
24 citations
,
June 2016 in “Acta dermato-venereologica” Tofacitinib helped a young woman's severe hair loss and arthritis but not her plaque psoriasis.
September 2024 in “Skin Appendage Disorders” Tofacitinib helped a woman regrow her hair without relapses after other treatments failed.
February 2025 in “PubMed” CS12192 effectively treats alopecia areata with better safety than current options.
July 2024 in “Journal of Investigative Dermatology” Tailored treatments for alopecia areata show promising results, with pulse steroids effective for mild cases and Ritlecitinib, Dupilumab, or methotrexate and prednisone effective for severe cases.
62 citations
,
April 2002 in “Journal of the American Academy of Dermatology” Sulfasalazine may help regrow hair in severe alopecia areata cases.
8 citations
,
July 2003 in “Annals of the Rheumatic Diseases” A 13-year-old girl with various symptoms was successfully treated with an antibiotic called co-trimoxazole.
January 2024 in “Pharmacoepidemiology” Patients with rheumatoid arthritis using tofacitinib had more serious side effects than those with alopecia areata.
August 1993 in “Journal of dermatological science” June 2025 in “British Journal of Dermatology” Tofacitinib is more effective than methotrexate for treating moderate-to-severe alopecia areata.
February 2011 in “Annales de dermatologie et de vénéréologie” Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.
18 citations
,
August 2024 in “eLife” JAK inhibition may help manage autoimmune conditions in Down syndrome.
February 2026 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib improves life quality for Alopecia Areata patients without worsening skin issues.
Upadacitinib and oral minoxidil improved Crohn's disease and hair regrowth in a patient.
February 2026 in “Dove Medical Press (Taylor and Francis Group)” Upadacitinib can effectively regrow hair in alopecia areata patients without worsening sarcoidosis.
The 1298CC genotype in RA patients leads to higher methotrexate toxicity, while the 1298AA genotype results in better treatment response.
4 citations
,
December 2024 in “Archives of Dermatological Research”
Cyclosporine is more effective than betamethasone for treating alopecia areata, despite mild side effects.
February 2010 in “Journal of The American Academy of Dermatology” Methotrexate treatment for rheumatoid arthritis has a serious infection rate of about two per 100 patient-years.
69 citations
,
December 2006 in “Archives of dermatology” Adalimumab may cause severe hair loss in some patients.
November 2015 in “Ankara Medical Journal” Weekly 5 mg folate is enough to prevent methotrexate toxicity in rheumatoid arthritis patients.
1 citations
,
January 2004 in “Linchuang pifuke zazhi” Topical cyclosporin-A is recommended for severe alopecia areata.
June 2026 in “Frontiers in Immunology” This case report highlights the successful use of upadacitinib, a selective JAK1 inhibitor, in treating a 57-year-old man with severe atopic dermatitis, vitiligo, and alopecia areata, conditions that share the JAK-STAT signaling pathway. Conventional therapies had failed, but upadacitinib (15 mg daily) led to rapid improvement: pruritus subsided within days, AD-related erythema cleared by 15 weeks, complete eyebrow regrowth occurred within months, and significant vitiligo repigmentation was observed at one year. The treatment was well-tolerated, suggesting that upadacitinib monotherapy could be an effective and well-tolerated option for these co-existing conditions, supporting a "multi-disease therapy" approach targeting common pathogenic pathways.
March 2025 in “Pediatric Rheumatology” Cyclophosphamide is preferred for severe cases in pediatric rheumatology and nephrology despite its side effects.
1 citations
,
April 2018 in “Journal of Investigative Dermatology” Simvastatin helps hair regrowth in autoimmune alopecia by directly affecting T cells.
42 citations
,
November 2018 in “Archives of dermatological research” Apremilast was not effective in treating moderate-to-severe alopecia areata.
1 citations
,
March 1989 in “The BMJ” A woman's hair grew back while she was taking sulphasalazine for arthritis.
5 citations
,
January 2021 in “Daru” A woman had severe reactions to methotrexate, including skin issues and organ problems, but improved after 38 days in the hospital.
10 citations
,
January 2018 in “International Journal of Trichology” Mesalazine may help treat extensive alopecia areata effectively.
21 citations
,
January 2013 in “Annals of dermatology/Annals of Dermatology” The combination of cyclosporine and PUVA might help treat severe alopecia areata.